Prognostic value of procalcitonin in cancer patients with coronavirus disease 2019 Journal Article

   


Authors: Tiutan, T.; Wallins, J. S.; Brown, S.; Gonen, M.; Korenstein, D.
Article Title: Prognostic value of procalcitonin in cancer patients with coronavirus disease 2019
Abstract: Objectives: Many biomarkers have been studied to assist in the risk stratification and prognostication of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Procalcitonin (PCT), a circulating precursor of the hormone calcitonin, has been studied with mixed results as a predictor of severe coronavirus disease 2019 (COVID-19) in the general population; however, to date, no studies have focused on the utility of PCT in predicting disease severity and death from COVID-19 in the cancer population. Methods: We conducted a retrospective study of cancer patients hospitalized with COVID-19 at a comprehensive cancer center over a 10-month period who had PCT recorded on admission. We assessed associations between variables of clinical interest and the primary outcomes of progression of COVID-19 and death during or within 30 days of hospitalization using univariable and multivariable logistic regression. Results: The study included 209 unique patients. In the univariate analysis, elevated PCT on admission was associated with higher odds of progression of COVID-19 or death (Odds ratio [OR] 1.40, 95% CI 1.08–1.93) and mortality alone (OR 1.53, 95% CI 1.17–2.11). In multivariate regression, PCT remained significantly associated with progression or death after holding chronic kidney disease (CKD) status constant (OR 1.40, 95% CI: 1.08, 1.93, p=0.003). Similarly, the association of PCT and death remained significant after adjusting for age (OR 1.54, 95% CI: 1.17–2.15). Conclusions: In hospitalized COVID-19 patients with underlying cancer, initial PCT levels on admission may be associated with prognosis, involving higher odds of progression of COVID-19 and/or mortality. © 2023 De Gruyter. All rights reserved.
Keywords: adult; controlled study; human tissue; aged; antibiotic agent; retrospective studies; major clinical study; mortality; cancer patient; outcome assessment; sensitivity and specificity; neoplasm; neoplasms; biomarkers; biological marker; disease association; reverse transcription polymerase chain reaction; neutrophil count; cohort analysis; retrospective study; cancer center; hospitalization; disease severity; death; hospital patient; hospital admission; systolic blood pressure; leukocyte count; disease exacerbation; oxygen saturation; chronic kidney failure; chronic obstructive lung disease; race; blood culture; clinical outcome; demographics; sputum culture; procalcitonin; cancer; humans; prognosis; human; male; female; article; coronavirus disease 2019; covid-19; sars-cov-2; nasopharyngeal swab; biomarkers of covid-19; prognostic factor of covid-19; progression of covid-19
Journal Title: Clinical Chemistry and Laboratory Medicine
Volume: 61
Issue: 2
ISSN: 1434-6621
Publisher: Walter de Gruyter & Co  
Date Published: 2023-01-01
Start Page: 339
End Page: 348
Language: English
DOI: 10.1515/cclm-2022-0366
PUBMED: 36367353
PROVIDER: scopus
PMCID: PMC9747503
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85142334197&doi=10.1515%2fcclm-2022-0366&partnerID=40&md5=e7b5cd193b88e30f900610b89556fd8e
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PubMed record and PDF. Corresponding author is MSK author Timothy Tiutan -- Export Date: 3 January 2023 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Mithat Gonen
    1028 Gonen
  2. Deborah Korenstein
    129 Korenstein
  3. Samantha Brown
    56 Brown
  4. Timothy Tiutan
    3 Tiutan
  5. Joseph Samuel Wallins
    3 Wallins
Related MSK Work